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Objective: We built a cohort study of HIV patients taking long-term first-line Antiretroviral Therapy in 2003. In this
assay, we focused on the development of primary drug resistance mutations against Non-Nucleoside Reverse
Transcriptase Inhibitor (NNRTI), K103N, Y181C and G190A.
Method: The cohort study was built in Henan province, China. We used Single Genome Amplification (SGA) to
analyze the frequency of K103N, Y181C and G190A in serial plasma samples of three individual patients. We also
performed standard genotype HIV drug resistance assay in 204 patients of this cohort study to analyze the frequency of
these mutations.
Result: In the SGA sequences, the K103N decreased and vanished, while the frequency of Y181C and G190A increased
in individual patient receiving long-term Antiretroviral Therapy (ART). In the sequences of standard genotype HIV drug
resistance assay, the frequency of K103N, Y181C and G190A had the similar pattern with that in SGA sequences. Among
these patients, the viral suppression were still sufficient after receiving ART for 72 months, and 78.6% (160/204) patients
could have their CD4 count over than 200cells/ul.
Conclusion: In some patients, first-line ART had the possibility to provide sufficient treatment effect for over than
72 months, but in long-term treatment, the dominant NNRTI drug resistance mutation K103N could reduced,
while the proportion of variants with mutation Y181C or G190A may increased. This result was not similar with
that in vitro study, which state that variant with K103N or Y181C had an equal viral fitness with wild type.
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Antiretroviral therapy (ART) in China started in 2003
[1], at the end of 2011, over 350,000 HIV-infected patients
were receiving ART [2]. Chinese national treatment guide-
lines for ART is: (1) CD4 cell count, 350/mm3 (increased
from 200/mm3 in 2008); (2) total lymphocyte count,
1,200/mm3; or (3) World Health Organization (WHO)
stage III or IV disease [3]. The first-line regimen in-
cluded two kinds of Nucleoside Reverse Transcriptase
Inhibitors (NRTI) and one kind of Non-Nucleoside* Correspondence: xingh@chinaaids.cn
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unless otherwise stated.Reverse Transcriptase Inhibitor (NNRTI) [4]. Because
of very limited antiretroviral drug formulations and lack of
adequate laboratory monitoring of ART patients, most pa-
tients who initiated ART during the early phase of the free
ART program had to stay on the same regimen for a long
period of time (maximum for 112 months in my research).
For this fact, the research on the development of drug re-
sistance mutations in long-term ART became more and
more necessary.
NNRTIs is a crucial component of Chinese ART, it
exhibit a longer plasma half-life and a longer duration
of detectable levels than nucleoside analog reverse tran-
scriptase inhibitors (NRTIs) [5]. Nevirapine (NVP) is an
acceptable first-line NNRTI for HIV-1-infected patients
[6] and is known as the most common NNRTI used intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of HIV-infected study population
on antiretroviral cohort study Henan Province, central
China




Median age at inclusion 39 (25–64)
Education
Primary school or less 218 (64.2)
Middle school or more 119 (35.8)
Marital status
Married or living with partner 287 (84.6)





Former plasma donor 327 (96.5)
Sexual transmitted 7 (2.1)
Unknown 5 (1.4)
Original combination antiretroviral regimen
Zidovudine, didanosine, nevirapine 288 (85.0)
Stavudine, didanosine, nevirapine 51 (15.0)
Stopped cART 34 (10.0)
Patients replacing ddI to 3TC 117 (34.5)
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took NVP as NNRTI in their regimens, and were never
been stopped and changed.
NVP is a potent NNRTI to fight against HIV, but it
has two drawbacks: one, it could cause allergic reactions
in approximately 5-14% of users worldwide [7-9], another
one is that NVP has a low genetic barrier; a single muta-
tion can lead to a high-level drug resistance against NVP
[10,11]. Among the NNRTI drug mutation, K103N,
Y181C and G190A are the most common mutation asso-
ciated with resistance to NVP [12,13]. Even in the patients
before ART, Low frequencies of K103N and Y181C are
significantly associated with an increased risk of virologic
failure [14]. In vitro study, K103N, Y181C and G190A
could not provide significant fitness reduction to HIV
viruses, variant with these mutations had similar viral repli-
cation fitness with the wild type variant [15,16]. In the past,
consider the low fitness reduction and high-level resistance
of NNRTI associated mutations, researchers seldom paid
attention to the NNRTIs resistant profiles resulting from
therapy failure, because a single NNRTI treatment failure
always means the second NNRTI therapy failure [17,18],
and in countries with rich ART resources, patients with
NNRTI drug resistance mutations would switch to new
regimen but in China, a country with limited antiretroviral
drugs, patients had to took same NNRTI drug for long
time, so the understanding of the development of NNRTI
associated mutations became very necessary.
In this essay, we retrospectively studied the development
of K103N, Y181C and G190A in long-term ART.
Method
Study population
National Center for AIDS/STD Control and Prevention
built an observational cohort study enrolled 339 patients
from Queshan County, Henan Province from December
2003 to December 2004. Patients who were 18 years of
age or older and started ART between 2003 and 2004
were included. All patients agreed to participate in the
study through informed consent. Patients were followed
every 6 months up to 11 November 2012. Due to stopping
ART, death or losing to follow-up. By the end of 2012,
among these 339 patients, 75 patients died for AIDS asso-
ciated diseases, 34 patients stopped ART, and 26 patients
lost to follow-up, so we had 204 patients for this study.
204 patients in this cohort study were all treated with
AZT/ddI/NVP (AZT, 300 mg 2 times/day; ddI, 200 mg
2 times/day; NVP, 200 mg, 2 times/day). Treatment adher-
ence was assessed by questionnaire in each follow-up. The
number of patients who had over 95% adherence in each
follow-up showed no significant difference (p > 0.05).
Sample collection was approved and done by Henan
CDC. In each follow-up, Neibor Joining phylogenetic ana-
lysis was performed to confirm that the longitudinalsamples were from the same patient, and all the infor-
mation of patients and the results of drug resistance
assays were all well stored by China CDC. All patients
took Nevirapine (NVP) as the NNRTI in regimen from
the initial time and have never been changed (Table 1).
To assess the ART outcome, the date of virologic failure
was defined as the first recorded date of plasma viral load
of more than 5000 copies/ml after 6 months of treatment,
as the 2010 WHO guideline on antiretroviral therapy for
HIV infection in adults and adolescents (WHO. Antiretro-
viral therapy for HIV infection in adults and adolescents:
recommendations for a public health approach. 2010).
Similarly, the date of immunologic failure was also defined
by WHO criteria as the earliest date of any one of the fol-
lowing after 6 months of treatment: posttreatment CD4+
cell count falling to or below baseline CD4+ cell count;
50% decrease from peak CD4+ cell count; or two con-
secutive CD4+ cell counts of less than 100 cells/ml or last
CD4+ cell count of less than 100 cells/ml. Baseline CD4+
cell count was defined as the last pretreatment count
within 6 months of treatment. If no pretreatment CD4+
cell count was done, the earliest count within 1 month
of starting treatment was used for the baseline value.
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points: treatment for 6–18 months; 30-42 months; 54-67
months and 75-102 months. Among the 204 patients, we
select 3 patients for Single Genome Amplification (SGA).
The criteria was (1) at least 6 time points; (2) no stopping
and restarting ART, (3) the results of CD4 count and viral
load were all available.
Laboratory methods
Standard genotype HIV drug resistance assay was per-
formed on the specimens in the four time points men-
tioned above. SGA were performed in 3 patients. They
were all performed in the National center for HIV/STD
diseases control and prevention, China CDC. In each
follow-up, viral load assays were performed by M2000
Biosystem (Abbott Company, USA). The CD4 cell count
for all patients were performed by FACSalibur flow
cytometer (BD Company, USA).
Viral RNA extraction and standard genotyping
Viral RNA were extracted from plasma samples using
QIAamp Viral RNA Mini Kit (QIAGEN company). We
used nested RT-PCR process to get a 1.3 kb (2253–3553)
fragment of pol gene, the fragment includes Protease amino
acid codons 1–99 and Reverse transcriptase amino acid co-
dons 1–300. The sequences of primers for the first round
RT-PCR process could be seen below: MAW265′-TTGG
AAATGTGGAAAGGAAGGAC-3 and RT215′-CTGTAT
TTCTGCTATTAAGTCTTTTGATGGG-3′. PCR temper-
ature was 50°C, 30 min for reverse transcription, 94°C,
10 min for preheat, followed by 94°C, 30 s; 55°C, 30 s; 72°C,
2 min 30 s, 30 cycles. 72°C 10 min for final amplification.
In the second round, we got a 1.3 kb fragment using
primer RT205′-CTGCCAGTTCTAGCTCTGCTTC-3′
and PRO15′-CAGAGCCAACAGCCCCACCA-3′. PCR
temperature was 94°C,10 min for preheat, followed by
94°C, 30 s; 55°C, 30 s; 72°C, 2 min 30 s, 30 cycles. 72°C
10 min for final amplification.
Single genome amplification (SGA)
RNA was extracted from plasma specimens by QIAamp
Viral RNA Mini kit (Qiagen, Germany), and was reverse
transcript to cDNA by SuperScriptIII protocol accord-
ing to the manufacturer’s instructions (Invitrogen Life-
Technologies, USA). We then dilute cDNA to a moderate
concentration in 96-well plates, such that fewer than 29
PCRs yielded an amplification product. According to
probability theory, once less than 30% PCR reactions get
positive results in 96-well plates, it has more than 80% to
get each sequence amplified from a single genome [19,20].
We used 3730 Sequencer (ABI company, USA) to get
sequences from all the positive amplification products,
and use Sequencher (4.10.1) to clean and edit sequence
data. In an individual sequence, if there is no ambiguousbase pair, it was confirmed that this sequence amplified
from a single genome. Finally, we got about 20 such sin-
gle genome sequences for each time point.
Data analysis (Ka/Ks Ratio of NNRTI associated mutations)
Ka/Ks ratio is a tool to characterize selection pressure
of observed amino acid mutations over observed syn-
onymous mutations, the ratio of the number of non-
synonymous substitutions per non-synonymous site (Ka)
to the number of synonymous substitutions per synonym-
ous site (Ks) [21]. Ka/Ks ratio was used as an indicator of
selective pressure acting on a protein-coding gene. A
Ka/Ks value of 1 indicates neutral selection, which means
amino acid changes are neither being selected for nor
against. A Ka/Ks value of < 1 means negative selection
pressure. That is, most amino acid changes are baneful
and are selected against. The positive selection (Ka/Ks > 1)
is much rare, indicating that amino acid changes are fa-
vored and may be useful [22].
The concept of correlated mutations is one of the basic
ideas in evolutionary biology. The amino acid substitution
rates are expected to be limited by functional constraints.
Given the functional constraints operating on gene, a mu-
tation in one position can be compensated by an additional
mutation. Then mutation patterns can be formed by corre-
lated mutations responsible for specific conditions. Here,
we used conditional Ka/Ks ratio (cKa/Ks), which is a
metric to measure the effects of mutations at one site on
the selection pressure for mutations at another site.
We conducted cKa/Ks ratio analysis on two dataset,
one is RT gene sequences of 204 patients using standard
HIV genotype sequencing, the other one is RT gene se-
quences of three patients using Single Genome Amplifi-
cation. In the two dataset, we had two time points, one was
receiving ART for 12 months (10–14 months), and the
other time point was receiving ART for over 60 months
(56–73 months).
In dataset one, because it is nearly impossible to get
gene sequence from plasma samples with suppressed viral
load, there were 75 sequences for the first time point, and
74 for the second time point, in dataset two, we had 99 se-
quences for the first time point and 109 for the second
time point. All the cKa/Ks analysis was done by R
Language, using the package CorMut (1.2.0, Zhenpeng Li ).
Ethics approval
Chinese Center for Disease Control and Prevention re-
search ethics boards approved this study.
Result
General information
Because of transferring to another clinic center, immigrat-
ing to other town, not all the 204 patients participated in
four follow-ups of this cohort study. There were 184, 148,
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respectively.
The median treatment duration [M(P25 ~ P75)] of the
204 patients was 86.4 months (77.6-98.0 mo). There were
46 patients receiving ART for over 100 months (22.5%).
Among the 204 patients, the main age range was 30–45
years (56.4%), maximum for 63, minimum for 24. Male fe-
male ratio was 0.6:1.
The frequency of K103N, Y181C and G190A in SGA
The frequencies of three primary NNRTI drug resistance
mutations, K103N, Y181C and G190A, fluctuated during
long-term ART. More specifically, K103N decreased, while
Y181C and G190A showed increasing trend (Table 2).
In the patient HENDRC593, the frequency of K103N
showed a decreasing trend, especially from 44.8 months,
the K103N vanished in SGA sequences. On the contrary,
G190A showed a dramatic increasing trend from the
initiation of ART.
In patients ANHDRC106, after taking ART for
23.9 months, K103N and Y181C became dominant muta-
tions (100%), while the frequency of G190A was 10%. In
the follow-up time points, K103N showed a decreasing
trend and G190A showed an increasing trend, while Y181C
maintained dominant.
In patients HENDRC622, K103N showed a decreasing
trend from 20.5 to 61.5 months, while G190A kept 100%Table 2 NNRTI mutations and treatment information for thre
ART duration Patient ID Viral load CD4 count K1
20.5 HENDRC593 500 498 6
27.5 500 691 8
38.9 2976 770 4
44.8 91000 655 3
49.9 120000 595 0
61.5 52000 696 0
76.1 170000 551 0
23.9 ANHDRC0106 44730 222 10
30.1 159000 196 5
35.5 94700 255 5
42.6 379000 153 3
46.4 17600 294 0
52.6 33100 256 1
20.5 HENDRC622 2076000 104 10
27.4 7263 164 14
33.0 17160 142 12
44.7 13160 138 9
49.9 66000 176 9
56.8 81000 130 4
61.5 39000 181 8in quasispecies. The Y181C increased slightly from 0.0% to
31.6% from receiving ART for 44.7 months to 61.5 months
The research of Jiong Wang [23] stated that mutation
K101E + G190S replicate better with NNRTI drug. Here
we showed the frequency of K101E in each time points.
It is interesting that the frequency of K101E changed
with G190A. In patient HENDRC593, the frequency of
K101E increased from 64.7% to 100% in 49.9 months,
while the frequency of G190A increased exactly from
64.7% to 100% in 49.9 months. In patient ANHDRC106,
the frequency of K101E increased from 0% to 100% in
46.4 months, while the frequency of G190A increased
from 10% to maximum 84.6% in 46.4 months. In patients
HENDRC622, the frequency of G190A kept in 100% in
nearly all time points, while the frequency of K101E kept
under 30%.
Standard genotyping: the frequency of K103N, Y181C and
G190A in long-term cohort study
All drug resistance assays were done by 20 December
2012. All the 204 patients took NVP from the initiation
of ART treatment and never changed to another NNRTI
drug. We collected the treatment and drug resistance
results in 4 time points of the 204 patients: 1.ART for
6-18 months; 2. ART for 30-42 months; 3. ART for 54-
67 months; 4. ART for 72-102 months. Then we calcu-
lated and analyzed the frequency of K103N, Y181C ande individual patients in SGA
03N G190A Y181C K101E SGA quantity
(35.3) 11 (64.7) 6 (35.3) 11 (64.7) 17
(42.1) 11 (57.9) 8 (42.1) 11 (57.9) 19
(26.7) 11 (73.3) 7 (46.7) 11 (73.3) 15
(15.8) 16 (84.2) 5 (26.3) 16 (84.2) 19
(0.0) 23 (100.0) 2 (8.7) 23 (100.0) 23
(0.0) 16 (94.1) 5 (29.4) 16 (94.1) 17
(0.0) 20 (100.0) 9 (45.0) 18 (90.0) 20
(100.0) 1 (10.0) 10 (100.0) 0 (0.0) 10
(41.7) 3 (25.0) 12 (100.0) 7 (58.3) 12
(33.3) 3 (20.0) 15 (100.0) 10 (66.7) 15
(21.4) 3 (21.4) 14 (100.0) 11 (78.6) 14
(0.0) 11 (84.6) 13 (100.0) 13 (100.0) 13
(7.1) 10 (71.4) 14 (100.0) 13 (92.9) 14
(83.3) 10 (83.3) 0 (0.0) 2 (16.7) 12
(93.3) 15 (100.0) 0 (0.0) 1 (6.7) 15
(75.0) 16 (100.0) 0 (0.0) 4 (25.0) 16
(81.8) 11 (100.0) 0 (0.0) 2 (18.2) 11
(90.0) 10 (100.0) 1 (10.0) 1 (10.0) 10
(22.2) 18 (100.0) 2 (11.1) 5 (27.8) 18
(42.1) 19 (100.0) 6 (31.6) 1 (5.3) 19
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K103N showed a decreasing trend while both the fre-
quency of Y181C and G190A showed an increasing
trend. Specifically, the frequency of K103N had a negative
correlation with treatment duration, and mutation G190A
had positive correlation with treatment duration. The fre-
quency of mutation Y181C and treatment duration did
not show significant correlation.
We also analyzed the frequency of K101E in 204 pa-
tients, but here we showed the correlated rate of K101E
and G190A in four time points, they were 3/9, 4/16, 7/23,
10/27 (about 30%).
Treatment effect in long-term Nevirapine-contain ART
At the time point of receiving ART for 6–18 months,
84.8% patients had their CD4 cells counts over 200 cells/
ml. At the time point of receiving ART for over 72 months,
there were still 78.6% (143/182) patients had their CD4
counts over 200 cells/ml.
For viral load, there were 39.1% patients failed to sup-
press their viral load in initial period (6–18 months). After


























































The frequency of K103N
The frequency of Y181C
Figure 1 The frequencies of three NNRTI drug resistance mutations in
treatment duration; b. the frequency of G190A with treatment duration; c.suppress their viral load; it indicated that the first-line
ART had the possibility to provide treatment effect in
55.5% patients (Table 3).
Besides the 204 patients, we had three patients per-
formed SGA experiments, all of them had received ART
for over 50 months, the maximum one is 76.1 months.
After long-term ART, the viral load were failed to be sup-
pressed sufficiently, but the CD4 count were kept steady
and were similar with the initial time of ART. The long-
term ART appeared to postpone the development of HIV
virus.
The correlated mutations with K103N, Y181C and G190A
(result of cKa/Ks ratio)
In the result of cKa/Ks analysis all positively correlated
mutations (cKa/Ks > 1) were listed here in Tables 4 and 5,
mutations with cKa/Ks smaller than 1 were not included
in the tables. Mutations in Position 1 were the condition
mutations, mutations in Position 2 were the accessory
mutations that were favored by ART with mutations in
Position 1. It showed that M41L, D67N, T69D, K70R, and



























K103N: Correlation coefficient=-0.972   p=0.028
Regression analysis: 
estimate frequency=-4.981   p=0.028
Y181C: Correlation coefficient= 0.691   p=0.310
Regression analysis: 
estimate frequency=2.21   p=0.309
G190A: Correlation coefficient= 0.9928   p=0.007
Regression analysis: 
estimate frequency= 4.97   p=0.007  
Time point
The frequency of G190A
K101E and G190A correlated rate 
in four time points:
3/9,  4/16,  7/23,  10/27
long-term ART treatment. a. the frequency of K103N with
the frequency of Y181C with treatment duration.
Table 3 Treatment effect of long-term ART in 204 patients
Treatment duration(months) Number of
patients
Patients with
CD4 > 200 cells/μl
Patients with
VL > LDL
Patients with NNRTIdr and
CD4 > 200 cells/μl
Patients with
NNRTIdr
6-18 184 156 (84.8%) 72 (39.1%) 34 (77.3%) 44
30-42 148 114 (77.0%) 95 (64.2%) 43 (76.8%) 56
54-67 200 147 (73.5%) 105 (52.5%) 49 (70.0%) 70
72-102 182 143 (78.6%) 81 (44.5%) 56 (77.8%) 72
notes:1. The number in this table refer to the number of certain patients, while proportions are in brackets.
2. VL refer to viral load,LDL refer to the lowest detectable viral load of certain method.
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Y181C and G190A. In NNRTI mutations besides K103N,
Y181C and G190A themselves, H221Y was the most com-
mon NNRTI mutations associated with the three NNRTI
mutations.
Among K103N, Y181C and G190A, some correlations
could be found, but they were not always positively cor-
related, the correlated mutations network changed with
the time of ART. For example, in standard genotype
sequencing dataset when receiving ART for 12 months
Y181C, G190A and H221Y were positively correlated with





ART for 12 months K103N NRTI M41L 1.5 7.05
NNRTI Y181C 1.29 5.17
G190A 1.6 5.22
H221Y 5 2.87
Y181C NRTI None None None
NNRTI H221Y 6 3.45
G190A NRTI None None None
NNRTI K103S 3 Inf
ART for over
60 months
K103N NRTI T69N 1.33 2.39
K70R 1.17 3.32
NNRTI Y181C 1.27 7.16
H221Y 2.75 5.5
Y181C NRTI D67N 1.8 3.77
T69N 2.5 5.85
K70R 5 4.95
NNRTI K103N 2 15.78
H221Y 4 6.05
G190A NRTI D67N 4.8 3.52
T69N 4 5.71
K70R 3 3.52
NNRTI K101E 6 3.52
Y181C 1.5 4.11
K103S 10 InfY181C and H221Y were positively correlated with K103N,
while G190A was not.
Besides the mutations conferring drug resistance effect,
there were a number of accessory mutations or compensa-
tory mutations that correlated with the three NNRTI
mutations, more specifically, 5 mutations for G190A in
12 months 14 ones for K103N, and 9 for Y181C. In the
dataset of receiving ART for over60 months, there were
35 mutations that correlated with G190A, 20 mutations
for K103N, and 26 mutations for Y181C. It indicated
that with the ART extended, more accessory mutations
would emerged.
Discussion
This research was based on a cohort study including 204
patients taking first-line ART therapy since early stage in-
fection. By the end of 2012, the median treatment duration
was 86.4 months (77.6-98.0 months), including 46 patients
received ART for over 100 months (22.5%). In our re-
search, after the ART treatment for over 72 months, 55.5%
patients had their viral load suppressed and 78.6% patients
kept CD4 counts over 200 cells/ml. It seems that the first-
line ART could still possibly be effective after long-term
treatment.
Though the first-line ART is potent method to fight
against HIV, but the development of drug resistance
could make ART less effective [24-27]. NNRTI associated
drug resistance mutations could compromise the success
of NNRTI-containing ART [28-30]. Among these muta-
tions, K103N Y181C and G190A are the most frequent
NNRTI associated drug resistance mutations. In a re-
search on nevirapine-experienced individuals, the frequen-
cies of these mutations were 43%, 46% and 26%
respectively [31]. Among the three NNRTI associated mu-
tations, K103N is one of the most clinically important
NNRTI resistance mutations; it causes 20- to 50-fold re-
sistance to most available NNRTIs [32,33]. In phenotypic
experiments, K103N, Y181C and G190A were defined as
the mutations that have almost the same replication
fitness with wild type. The rank of fitness among mu-
tant viruses was as follows: wild type (WT) ≥ Y181C ≥
K103N ≥G190A ≥ V106A ≥ P236L ≥G190S [34,35]. Be-
sides the replication fitness, K103N can persist for a long
time in naive patients, over 2 years in a present case report





ART for 12 months
K103N NRTI D67N 5 2.93
T69D 8 Inf
K70R 16 9.37
NNRTI Y181C 26 15.23
H221Y 17 9.96
Y181C NRTI D67N 5 2.93
T69D 8 Inf
K70R 1.12 5.27
NNRTI K103N 2 29.44
H221Y 17 9.96
G190A NRTI None
NNRTI K101E 29 16.98
ART for over
60 months
K103N NRTI T69D 12 Inf
NNRTI K219R 88 6.75
Y181C NRTI D67N 11.5 14.12
T69D 2 Inf
NNRTI K103N 2.25 9.41
H221Y 26 15.96
G190A NRTI M41L 21.25 88.84
D67N 7.33 13.51
T69D 12 Inf




Note: Ckaks indicates the ka/ks ratio of two mutations. Here, it stands for the
ka/ks ratio for M184V and the correlated mutations.
Lod is the confident score for positive selection, If LOD >2, the positive
selection is significant.
Inf indicates the maximum infinity.
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cell (PBMC) DNA, with no K103N observed in plasma
[37,38]. All the previous research indicated that K103N
can steadily exist in plasma and PBMC, and quasispecies
with K103N could be more possibly to survive in the sur-
rounding with NVP.
In our research, the result was different with that in vitro
study. We found that during the long-term ART treatment,
the frequency of K103N, Y181C and G190A were not
kept steady, the fact is the frequency of quasispecies
with K103N decreased, and could even vanish in SGA
sequences, while the proportion of Y181C and G190A
could increase from 0% to nearly 100%. This result was
also identified in a 204-patinets long-term cohort study.Based on the results, we estimated that among the
three strong NNRTI drug resistance mutations, K103N,
Y181C and G190A, there may be some competition
process in long-term ART. In the initial period of NVP-
containing ART, K103N, Y181C and G190A emerged in
different rate among quasispecies which K103N and
G190A had a higher rate than Y181C [39]. Consider the
fact that three mutations have similar replication fitness
and the replication fitness which are associated with mu-
tant prevalence in vivo [40-42]. Mutation emerged late
would develop to the proper proportion associated with
its replication fitness, while the proportion of mutation
emerged earlier would reduced because the late emerged
mutation took part of its dominant role. Then these three
mutations would finally break the imbalanced and unequal
proportion which was established in initial ART period.
The result of cKa/Ks ratio could provide another sup-
port for the competition hypothesis. Among the K103N,
Y181C and G190A, they were not always positively
correlated with each other, but may turn to negative
correlation with the time of receiving ART. It indicated
that although in vitro study, the three mutations all had
high replication rate and less viral fitness reduction than
other NNRTI mutations, variants with these mutations
were not so strong in vivo when existed in plasma at same
time, they were not always favored by variant under ART
pressure. Some competition effect among them may
change the frequency of these mutations.
Here is a question according to the research of Jiong
Wang [42], the reduced fitness for G190A mutants may
not explain the increased frequency of G190A variants
over time. It is true that G190A alone can reduce viral
fitness, but another research of Jiong Wang [23] found that
the variant with K101E +G190S replicated better in the
presence of NNRTIs than in the absence of drug, it indi-
cate that mutation K101E may have some effect on the
mutant of Codon 190 to enhance the viral fitness. In our
study, the frequency of K101E had a similar trend with that
of G190A in SGA result, and nearly 30% (3/9, 4/16, 7/23,
10/27) K101E emerged with G190A in standard genotyp-
ing result. This may partly explain the question that the
increasing of G190A frequency in long-term ART.
The further mechanism and detail of the competition
process were remaining unclear; we may need next-
generation sequencing and other techniques to go deep in
this question. At least we believe this changing of NNRTI
mutations is crucial in long-term ART treatment, especially
for the country with limited antiviral drugs.Abbreviations
HIV: Human immunodeficiency virus; ART: Antiretroviral therapy;
NRTI: Nucleoside reverse transcriptase inhibitors; NNRTI: Non-nucleoside
reverse transcriptase inhibitors; PCR: Polymerase chain reaction;
TAMs: Thymidine analogue mutations.
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